NCT05298332View on ClinicalTrials.gov

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

August 22, 2022

Study Completion Date

August 22, 2022

Conditions
Chronic Hepatitis b
Interventions
DRUG

ATI-2173 50 mg

ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)

Trial Locations (1)

90630

Altasciences, Cypress

Sponsors
All Listed Sponsors
lead

Antios Therapeutics, Inc

INDUSTRY

NCT05298332 - Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects | Biotech Hunter | Biotech Hunter